| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human CHRNA2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于CHRNA2抗体的假设性参考文献示例(注：文献为虚构，仅供格式参考)：
---
1. **文献名称**：*CHRNA2 subunit expression in hippocampal neurons: An immunohistochemical study*
**作者**：Smith A, et al.
**摘要**：本研究利用特异性CHRNA2抗体，通过免疫组化技术揭示了α2烟碱受体亚基在海马体CA1区锥体神经元中的高表达，并发现其在癫痫模型中表达水平显著下调。
2. **文献名称**：*Role of CHRNA2 in nicotine addiction: Antibody-based localization in mouse brain*
**作者**：Chen L, et al.
**摘要**：通过Western blot和免疫荧光技术，验证了CHRNA2抗体在小鼠前额叶皮层及伏隔核中的特异性标记，证实α2亚基参与尼古丁成瘾相关神经环路调控。
3. **文献名称**：*CHRNA2 genetic variants and protein expression in schizophrenia postmortem brains*
**作者**：Rodriguez M, et al.
**摘要**：结合基因测序与CHRNA2抗体免疫印迹分析，发现精神分裂症患者丘脑组织中CHRNA2蛋白表达异常，与特定单核苷酸多态性(SNP)存在关联。
---
*注：以上文献为模拟内容，实际研究需通过PubMed或学术数据库检索。若需真实文献，建议使用关键词“CHRNA2 antibody”+“expression”/“localization”/“[疾病名称]”进行查询。*
The CHRNA2 antibody targets the alpha-2 subunit of neuronal nicotinic acetylcholine receptors (nAChRs), ligand-gated ion channels critical for cholinergic signaling in the nervous system. Encoded by the *CHRNA2* gene, this subunit assembles with other nAChR subunits (e.g., β2. β4) to form heteromeric receptors, primarily expressed in the central nervous system. These receptors modulate synaptic transmission, influencing processes like cognition, reward pathways, and neurotransmitter release. CHRNA2-specific antibodies are essential tools for studying receptor localization, expression levels, and functional roles in health and disease.
Research using CHRNA2 antibodies has linked the subunit to neurological conditions, including epilepsy, nicotine addiction, and neurodevelopmental disorders. For example, mutations in *CHRNA2* are associated with autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE). Antibodies enable detection via techniques like Western blot, immunohistochemistry, or flow cytometry, often validated using knockout controls to ensure specificity.
Recent studies also explore CHRNA2's role in synaptic plasticity and its interaction with neuropsychiatric drugs. Understanding CHRNA2 dynamics aids in deciphering cholinergic circuit dysfunctions and developing targeted therapies. However, challenges remain in distinguishing CHRNA2-containing receptors from other nAChR subtypes due to structural similarities. Despite this, CHRNA2 antibodies remain pivotal in advancing both basic neuroscience and clinical research.
×
